Dr. Merker is a pharmacologist who conducted his doctoral work in pharmacology at Purdue University. He minored in physiology and did additional coursework in pharmaceutical chemistry. His graduate thesis was in the field of tissue deposition of drugs. Dr. Merker received a M.S. degree from Purdue University, also majoring in pharmacology. he received a B.S. degree from Long Island University, majoring in pharmacy. Dr. Merker is a licensed pharmacist in the states of New York and Tennessee. He is a member of the American Society of Pharmacology and Experimental Therapeutics, the American Society for Experimental Pathology, the American Association for Cancer Research, and the Society of Toxicology. Dr. Merker joined the staff of Richardson-Vicks, Inc., in 1977.
Areas of research in which he has experience include endocrinology, biochemical pharmacology with interest in glycolysis and oxidative phosphorylation, cardiovascular pharmacology, gastroenterology, development of experimental tumor transplantation systems, experimental cancer chemotherapy, carcinogenesis, and neuropharmacology. Dr. Merker is the author of approximately 70 publications covering various aspects of these topic areas.
Dr. Merker also has been involved as a consultant for the National Institutes of Health, National Cancer Institute, in the areas of tumor transplantation, cancer chemotherapy, and endocrine sensitive transplantable tumors.
He has acted as a consultant to a number of pharmaceutical companies, primarily in cancer chemotherapy and cardiovascular pharmacology. He was the principal organizer of a large cooperative university-pharmaceutical company research venture.
In the field of education, Dr. Merker has served as professor of pharmacology and head of a department of biological sciences and pharmacology. In these capacities, he has involved in the development of coordinated curriculum planning, analysis and development of curricula for paramedical professional schools, and the development of community-oriented drug information programs. Currently, as Adjunct Professor of Pharmacology, New York Medical College, he organized and lectures in a graduate-level course in toxicology.
He has been directly involved in management, as chairman, vice chairman, and member of committees of industry associations, as well as a cooperative, industry wide, long-term carcinogenesis testing program that also required direct interaction with the FDA for purposes of planning and discussions. He has planned with and integrated the activities of scientists in the disciplines of pharmacology, toxicology, biostatistics, biochemistry, and pharmacokinetics.
Dr. Merker, in his position as Director of Pharmacology and Toxicology, Richardson-Vicks, has managed and participated in drug development projects entailing the integration of pharmacological, toxicological, and pharmacokinetic testing. In this capacity, he has participated in FDA discussions and planning about new drug development in the filing of IND's and NDA's.
Dr. Merker's wife, Alta, is a retired biochemist. Their daughter, Marilyn Merker Goldman, has her Ph.D. in pharmacology, their son Edward, is a physician.